Immunic Inc
IMUX0.950USD
+0.019+2.01%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
85.66MCap. mercado
PérdidaP/E TTM
Más Datos de Immunic Inc Compañía
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.
Información de la empresa
Símbolo de cotizaciónIMUX
Nombre de la empresaImmunic Inc
Fecha de salida a bolsaApr 17, 2014
Director ejecutivoDr. Daniel Vitt, Ph.D.
Número de empleados91
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 17
Dirección1200 Avenue Of The Americas
CiudadNEW YORK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10036
Teléfono13322559818
Sitio Webhttps://imux.com/
Símbolo de cotizaciónIMUX
Fecha de salida a bolsaApr 17, 2014
Director ejecutivoDr. Daniel Vitt, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Daniel Vitt, Ph.D.
Dr. Daniel Vitt, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
391.88K
+3.98%
Dr. Joerg Neermann, Ph.D.
Dr. Joerg Neermann, Ph.D.
Independent Director
Independent Director
200.00K
+100.00%
Mr. Glenn Whaley, CPA
Mr. Glenn Whaley, CPA
Chief Financial Officer
Chief Financial Officer
95.51K
+89.09%
Dr. Duane D. Nash, M.D.
Dr. Duane D. Nash, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
42.03K
+90.78%
Mr. Jason Tardio
Mr. Jason Tardio
President, Chief Operating Officer
President, Chief Operating Officer
12.51K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
--
--
Dr. Andreas Muehler, M.D.
Dr. Andreas Muehler, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Inderpal Singh
Mr. Inderpal Singh
General Counsel
General Counsel
--
--
Ms. Maria Toernsen
Ms. Maria Toernsen
Independent Director
Independent Director
--
--
Dr. Hella Kohlhof, Ph.D.
Dr. Hella Kohlhof, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Daniel Vitt, Ph.D.
Dr. Daniel Vitt, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
391.88K
+3.98%
Dr. Joerg Neermann, Ph.D.
Dr. Joerg Neermann, Ph.D.
Independent Director
Independent Director
200.00K
+100.00%
Mr. Glenn Whaley, CPA
Mr. Glenn Whaley, CPA
Chief Financial Officer
Chief Financial Officer
95.51K
+89.09%
Dr. Duane D. Nash, M.D.
Dr. Duane D. Nash, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
42.03K
+90.78%
Mr. Jason Tardio
Mr. Jason Tardio
President, Chief Operating Officer
President, Chief Operating Officer
12.51K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BVF Partners L.P.
9.29%
abrdn Inc.
8.60%
Soleus Capital Management, L.P.
7.61%
Avidity Partners Management LP
4.65%
The Vanguard Group, Inc.
4.10%
Other
65.74%
Accionistas
Accionistas
Proporción
BVF Partners L.P.
9.29%
abrdn Inc.
8.60%
Soleus Capital Management, L.P.
7.61%
Avidity Partners Management LP
4.65%
The Vanguard Group, Inc.
4.10%
Other
65.74%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
26.20%
Investment Advisor
13.30%
Investment Advisor/Hedge Fund
11.31%
Individual Investor
1.36%
Research Firm
1.05%
Pension Fund
0.06%
Other
46.74%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
135
51.29M
53.53%
-8.04M
2025Q1
143
43.91M
45.87%
-16.90M
2024Q4
141
54.47M
60.46%
-15.06M
2024Q3
152
61.42M
68.19%
-8.79M
2024Q2
169
63.34M
74.84%
-9.30M
2024Q1
202
64.86M
76.52%
-3.93M
2023Q4
199
22.30M
46.89%
-13.27M
2023Q3
205
25.26M
53.96%
-11.93M
2023Q2
209
27.09M
58.47%
-12.08M
2023Q1
208
31.66M
68.86%
-6.82M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BVF Partners L.P.
8.90M
9.29%
--
--
Mar 31, 2025
abrdn Inc.
1.06M
1.11%
+1.06M
--
Mar 31, 2025
Soleus Capital Management, L.P.
7.29M
7.61%
--
--
Mar 31, 2025
Avidity Partners Management LP
4.45M
4.65%
-3.51M
-44.09%
Mar 31, 2025
The Vanguard Group, Inc.
3.93M
4.1%
+7.79K
+0.20%
Mar 31, 2025
Focus Partners Wealth, LLC
2.58M
2.7%
+415.10K
+19.14%
Mar 31, 2025
Gratus Capital LLC
2.11M
2.2%
+56.86K
+2.77%
Jun 30, 2024
Omega Fund Management, LLC
1.79M
1.87%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
1.40M
1.46%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
976.15K
1.02%
+23.86K
+2.51%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proporción0.02%
Invesco NASDAQ Future Gen 200 ETF
Proporción0%
Avantis US Small Cap Equity ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
